RxDoctor Payments DataLook up a doctor →

Ronald Drescher, PA

Physician Assistant · Clinton, UTNPI 1942306956

Payments from drug & device makers

$6,748in general payments, 2019–2025

Across 424 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$604
  • Astellas Pharma US Inc$449
  • Lilly USA, LLC$441
  • AstraZeneca$359
  • Pfizer$334
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,54897%
  • Education$2003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,748 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$82,515
Medicare patients
159
Services billed
5,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$43,583
OzempicSemaglutide38$39,882
MounjaroTirzepatide32$33,519
EliquisApixaban27$25,773
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$24,072
RexultiBrexpiprazole13$22,202
TrulicityDulaglutide18$17,238
MyrbetriqMirabegron25$16,364
FarxigaDapagliflozin Propanediol21$14,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,327
JanumetSitagliptin Phos/Metformin Hcl23$12,938
LinzessLinaclotide13$9,072
XareltoRivaroxaban12$8,144
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,435
TradjentaLinagliptin11$6,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$441$50,75750 claims
Boehringer IngelheimJardiance, Tradjenta$312$50,16674 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$359$41,72669 claims
Novo NordiskOzempic$169$39,88238 claims
PfizerEliquis$334$25,77327 claims
Otsuka America Pharmaceutical, Inc.Rexulti$40$22,20213 claims
Astellas Pharma US IncMyrbetriq$449$16,36425 claims
GSKTrelegy Ellipta$604$13,32721 claims
MerckJanumet$93$12,93823 claims
AbbVieLinzess$1,280$9,07213 claims
Johnson & JohnsonXarelto$223$8,14412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Clinton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →